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A series of mitochondrially inherited mutants of yeast has been analysed, which were previously identified as showing 
resistance tothe antibiotics venturicidin or ossamycin and whose mutations showed tight linkage to oligomycin-resistance 
alleles affecting subunit 9 of the mitochondrial ATP synthase. DNA sequence analysis of the olil gene of these mutants 
has been used to define the nature of amino acid substitution i  the subunit 9protein. In the case of the two venturicidin- 
resistant mutants, mutations affect amino acids on the N-terminal stem of the protein, namely Gly25~Ser (ven Ross  
oli R) and Ala 27~Gly (ven Ross oliS). The mutations found in the two ossamycin-resistant mu ants affect amino acids 
on the C-terminal stem of the protein, namely Leu53--*Phe (van soss R oli R) and Leu57--*Phe (ven soss R oliS). These results 
allow us to further develop afine structure map of domains within the subunit 9protein involved in antibiotic interaction. 
ATPase complex, mitochondrial; Amino acid substitution; Venturicidin; Ossamycin; Drug-resistance domain; Gene, olil; 
( Saccharomyces revisiae) 
1. INTRODUCTION 
The yeast mitochondrial o il gene encodes the 
dicyclohexylcarbodiimide-binding proteolipid sub- 
unit 9 of the mitochondrial ATP synthase complex 
[1]. Subunit 9 is a 76 amino acid proteolipid which 
resides in the membrane F0 sector of the mitochon- 
drial ATP synthase (mtATPase) and plays a major 
role in the proton-translocation activity of the en- 
zyme complex [2]. Subunit 9 adopts a hairpin 
structure in the inner mitochondrial membrane, 
with two transmembrane st ms and a hydrophilic 
loop [3] which is thought o interact with the F~ 
Correspondence address: P. Nagley, Department of 
Biochemistry, Monash University, Clayton, Victoria 3168, 
Australia 
Abbreviations: mtATPase, mitochondrial proton-translocating 
ATP synthase; mtDNA, mitochondrial DNA; ven R, venturici- 
din-resistant; oss R, ossamycin-resistant; oliR, oligomy- 
cin-resistant (in reference to phenotype) 
sector of the enzyme on which ATP synthesis oc- 
curs. The drugs venturicidin, ossamycin and 
oligomycin all act to block proton-translocation 
through the membrane-associated Fo sector of the 
mtATPase [4], interacting particularly with sub- 
unit 9 [5]. In previous work, direct amino acid se- 
quence analysis of the subunit 9 protein [6] and 
nucleotide sequence analysis of the olil gene of 
oligomycin-resistant (oli R) mutants [7] revealed 
amino acid substitutions on the C-terminal stem in 
the vicinity of Glu59 and on the N-terminal stem of 
the protein close to Gly23. Analysis of those oli g 
mutants which showed cross-resistance to venturi- 
cidin suggested that the domain of resistance to 
venturicidin lies entirely within the oligomycin- 
resistance domain [8]. 
Another set of mutants, isolated primarily on 
the basis of their venturicidin-resistant (ven R) or 
ossamycin-resistant (oss R) phenotype, has been 
subjected to extensive genetic analysis (including 
petite deletion analysis and recombination studies 
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Table 1 
Molecular genetic haracteristics of drug-resistant strains affected in the olil gene 
June 1989 
Strain Allele designation Phenotype DNA Nucleotide Codon Codon Amino 
sequence change number change acid 
Previous Current number change 
D22/61 vR61 0lil-61 vengoli R +73 G----,A 25 GGU-----~AGU Gly----~ Ser 
D22/60 VR60 01il -60 ven R + 80 C ~ G 27 GCU---"  GGU Ala ~ Gly 
D27/110 olir-ll0 oli1-110 oIiRoss R + 159 A----*T 53 UUA-----~UUU Leu----*Phe 
D27/101 ossr-101 01i1-111 OSS R + 171 A----* C 57 UUA----* UUC Leu----* Phe 
[4,9]). Although these analyses howed that these 
mutations were mitochondrially inherited and 
tightly linked to representative alleles of the olil 
locus, the definitive fine structure genetic mapping 
of this set of mutations was not possible [9]. 
In this work a series of four mutants in this 
group, resistant to venturicidin or ossamycin, have 
been studied by DNA sequence analysis of the olil 
gene. The definition of the nucleotide substitutions 
allows correlations to be made with recombina- 
tional analyses; the consequent amino acid changes 
extend our insight into domains within subunit 9 
involved in interactions with antibiotics. 
2. MATERIALS AND METHODS 
2.1. Strains 
The strains of Saccharomyces cerevisiae analysed here (table 
1) were isolated by W.E. Lancashire [4,9], and were available 
in the collection maintained in Colorado. These mutants were 
primarily selected for their resistance to venturicidin or 
ossamycin; relevant cross-resistance patterns are shown in table 
1. A systematic designation of the allele number is given for 
each mutation, together with the original denotation (table 1). 
2.2. Methods 
Growth of strains, extraction of mtDNA and nucleotide se- 
quence determination of the olil gene were carried out as 
described [7]. 
3. RESULTS AND DISCUSSION 
3.1. Nucleotide and amino acid sequence changes 
The single nucleotide changes observed relative 
to the J69-1B wild-type sequence, together with the 
consequent amino acid substitutions, are shown in 
table 1. Strain D22/61 is resistant to both 
oligomycin and venturicidin. Its mutation leads to 
the amino acid substitution Gly25 , Ser; it is 
thus distinct from previously characterised 
venRoli R mutants ubstituted at Gly23 [8]. 
Strain D22/60 represents a class of mutant not 
previously analysed at the molecular level, resis- 
tant to venturicidin but sensitive to oligomycin. 
The mutation in this mutant leads to the amino 
acid substitution Ala27 , Gly. Thus, the muta- 
tions in both D22/61 and D22/60 lead to changes 
in subunit 9 located in the N-terminal stem very 
close to the previously recognised oligomycin- 
resistance substitutions at Ala22 [10] and Gly23 
[7,8]. 
Two ossamycin-resistant mutants were also 
analysed. Strain D22/110 (ossRoIi R) contains the 
amino acid substitution Leu53 ~ Phe. Precisely 
the same mutation affecting Leu53 has been shown 
in many cases to be associated with an oliRven s
phenotype [5]; presumably, in most instances 
resistance to ossamycin was not tested. Perhaps the 
ossRoIi R phenotype of D27/110 is characteristic of 
the Leu53 , Phe substitution; alternatively, the 
oss R phenotype may be elicited specifically in this 
strain by other as yet unidentified mitochondrial or 
nuclear factors. For example, when the mtDNA of 
a oliRven R mutant (0851) carrying the subunit 9 
substitution Phe64 ~ Leu, is transferred into dif- 
ferent nuclear backgrounds, the resulting strains 
show varying resistance to venturicidin [8]. 
Strain D27/101, which is oss R but showed no 
cross-resistance to other drugs tested, carries the 
amino acid substitution Leu57 , Phe. This par- 
ticular mutation at Leu57 has not been observed 
before and is of interest because another substitu- 
tion at the same position, Leu57 , Val, leads to 
the oliRven R phenotype [6]. No data on the 
ossamycin-resistance of the latter strain 
(D273-10B/A68) have been reported. 
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3.2. Correlation of  recombinational data with 
location of  mutation 
Whilst attempts at the fine-structure genetic 
mapping of drug-resistance mutations in the olil 
gene using recombinational nalysis yielded much 
data, no coherent mapping of alleles, or even of 
loci defined by phenotype, could be obtained until 
amino acid and DNA sequence analyses were ap- 
plied [6,7]. 
These problems can be illustrated with reference 
to genetic recombinational data reported for the 
mutations analysed here. Recombinational naly- 
sis [4] of the mutations in the strains D22/60 and 
D22/61 yielded an observed recombinational fre- 
quency of 1.5070, suggesting that these mutations 
are some distance apart. Yet the DNA sequence 
analysis carried out in this work (table 1) shows 
that these mutations are only 7 base pairs apart in 
the olil gene. By contrast, the mutation in D22/60 
was found to yield a recombination frequency of 
<0.207o with the reference olil-1 allele [4]. This 
olil-1 mutation has been assigned by DNA se- 
quence analysis to nucleotide + 159, which is 86 
base pairs away from the mutation in D22/61 
(nucleotide + 73; table 1). Moreover, the mutation 
in D22/61 was found to recombine with a frequen- 
cy in the order of 0.1070 when crossed to 
D273-10B/A68 carrying the oli l- l l9 mutation 
(localised to nucleotide + 170 [6]). Nevertheless, in
a separate study the mutation in D22/61 was found 
to recombine with the olil-1 mutation (nucleotide 
+ 159) at a frequency of 3-4070 [4]. The molecular 
rationalization of these erratic recombination fre- 
quencies is not understood. 
On the other hand, similar analyses carried out 
for the mutations of D27/101 and D27/110 
showed recombinational data to be consistent with 
the DNA sequence analysis. Thus, the mutation in 
D27/110 was not found to show detectable recom- 
bination with the olil-625 mutation (nucleotide 
+ 159) in strain CD9 [9], consistent with the pre- 
sent demonstration that the mutations are precisely 
allelic. Moreover, the mutation in D27/101 was 
found to recombine at a frequency of 0.3070 with 
the olil-625 mutation [9] consistent with the 
demonstrated physical separation of their muta- 
tions by 12 base pairs on the olil gene. It is clear 
that the most definitive way to map the mutations 
in such drug-resistant mutants is direct DNA se- 
quence analysis of the olil gene of these mutants. 
Similar considerations apply to the oli2 gene where 
several drug-resistance mutations are clustered 
within a 250 base pair block [11,12]. On the other 
hand the mapping of drug-resistant mutations on 
the yeast mitochondrial COB gene encoding 
cytochrome b is generally more reliable because of 
the much greater physical distance between alleles 
[131. 
3.3. Domains of  subunit 9 involved in inhibitor 
interaction 
The amino acid substitutions in subunit 9 
generated by the nucleotide sequence changes 
reported here give further insight into the domains 
of this protein involved in drug interaction. 
Together with all the amino acid substitutions thus 
far recognised in S. cerevisiae subunit 9, this new 
information ot only allows for further expansion 
of the previously defined oligomycin- and 
venturicidin-binding domains of the protein but 
also allows for the definition of an ossamycin- 
resistance domain. The drug-resistance domains, 
within which the reported amino acid substitutions 
lie are shown in fig. 1. The oligomycin- and the 
venturicidin-resistance domains are centred on 
amino acids 23 and 59 and encompass both the N- 
terminal and C-terminal stems of the protein. The 
venturicidin-resistance domain was previously 
thought to lie entirely within the oligomycin- 
binding domain [10]. Whilst the substitution at 
amino acid 25 in the venRoli R mutant D22/61 is 
consistent with this generalisation and extends the 
common domain, the substitution at amino acid 27 
arising in the ven R mutant D22/60 indicates that 
the venturicidin-binding domain does not lie en- 
tirely within the oligomycin-binding domain at this 
point. There are thus two overlapping, but in- 
dependent domains for resistance to these in- 
hibitory drugs, which is not altogether surprising 
in terms of their very different chemical structures. 
The amino acid substitutions leading to 
ossamycin resistance in the mutants D27/101 and 
D27/110 lie in close proximity to each other on the 
C-terminal stem of the protein at amino acids 57 
and 53, respectively. As these amino acids also lie 
close to the boundaries of the oligomycin- and 
venturicidin-resistance domains it may be inferred 
that this region of the protein interacts in some 
way with all three inhibitors. 
It is of interest that a further ossamycin- 
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Fig. 1. Intra-membrane domains of drug resistance of subunit 9 
in yeast mtATPase. The subunit 9 polypeptide is represented in 
a hairpin configuration [2,5], spanning the membrane [3]. The 
membrane domains of resistance to either oligomycin (thin 
lines) or to both oligomycin and venturicidin (thick lines) in the 
membrane-internai portion of subunit 9 are indicated. Amino 
acid substitutions conferring ossamycin-resistance or 
venturicidin-resistance, id ntified in this paper, are circled. The 
ossamycin-resistance phenotype of all mutants carrying the 
substitution Leu53 ,Phe is not certain (see text). 
res istance mutat ion  in the yeast mi tochondr ia l  oli2 
gene (allele des ignated 0ss'1-92), has been shown 
to direct  the subst i tut ion o f  an amino  acid in 
subuni t  6 o f  mtATPase  (Asp254 ,Asn)  which is 
con jec tured  to lie outs ide the membrane  [11]. The 
molecu la r  detai ls o f  the in teract ion  o f  ossamyc in  
with subunits  9 and 6 both  with in  and outs ide the 
membrane  remain  to be establ ished. 
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